title: [Expression and clinical significance of plasma small RNA in patients with pancreatic cancer].
abstract: OBJECTIVE
  The aim of this study was to identify six miRNAs expressed in plasma of patients with pancreatic cancer (PCa) and analyze their value as a diagnostic index of pancreatic cancer.
  
  
  METHODS
  Plasma total RNAs were extracted from 30 PCa patients and 26 normal controls, and the abundance of six microRNAs was measured using real-time PCR. The possibility to combine them with CA19-9 as diagnostic biomarkers was analyzed.
  
  
  RESULTS
  The expression level of miR-21, miR-210, miR-155, miR-20a, miR-25 and miR-196a in plasma of patients with pancreatic cancer were 1.65×10(6), 5.98×10(4), 2.83×10(3), 3.47×10(6), 2.76×10(6), and 1.03×10(3) (copies/µl), while the normal controls were 4.08×10(5), 2.54×10(4), 8.55×10(2), 1.79×10(6), 9.32×10(5), and 4.67×10(2) (copies/µl), respectively, with a significant difference between the two groups (P < 0.05). The areas under the ROC curve of miR-21, miR-210, miR-155, miR-20a, miR-25 and miR-196a were 0.893, 0.810, 0.820, 0.766, 0.816 and 0.729, respectively. MiR-21 had the highest diagnostic value when it was used as diagnostic marker alone. The combination of miR-155 and miR-25 was more effective to distinguish PCa from normal than to be used alone, and the area under the ROC curve was 0.913 (95%CI 0.838-0.988) .When CA199 associated with miR -210 and miR-25, respectively, the areas under the ROC curves were 0.96 (95%CI was 0-1.0) and 0.942 (95% CI was 0.876-1.0), which were higher than CA199 alone (0.862, 95%CI was 0.748-0.975). There was a high improvement in diagnostic sensitivity and accuracy when miR-210 and miR-25 were combined with CA19-9, respectively.
  
  
  CONCLUSIONS
  Plasma miR-21, miR-155, miR-25, miR-210 have diagnostic value for pancreatic cancer, and deserve further study.
authors.affiliation: Department of Gastroenterology, Qianfoshan Hospital, Shandong University, Jinan 250014, China.
authors.forename: Wenzheng
authors.initials: W
authors.lastname: Pan
authors.forename: Wanyan
authors.initials: W
authors.lastname: Tang
authors.forename: Wei
authors.initials: W
authors.lastname: Yuan
authors.forename: Qi
authors.initials: Q
authors.lastname: Yu
authors.forename: Wen
authors.initials: W
authors.lastname: Zuo
authors.affiliation: Email: xcqys@126.com.
authors.forename: Changqing
authors.initials: C
authors.lastname: Xu
authors.affiliation: Email: majie1965@163.com.
authors.forename: Jie
authors.initials: J
authors.lastname: Ma
mesh_terms: D000368:Aged; D014408:Biomarkers, Tumor / Q000097:blood / Q000235:genetics; D018395:CA-19-9 Antigen / Q000097:blood; D016022:Case-Control Studies; D005260:Female; D006801:Humans; D008297:Male; D035683:MicroRNAs / Q000097:blood*; D008875:Middle Aged; D010190:Pancreatic Neoplasms / Q000097:blood* / Q000175:diagnosis* / Q000235:genetics; D012372:ROC Curve; D060888:Real-Time Polymerase Chain Reaction
chemical_list: D014408:Biomarkers, Tumor; D018395:CA-19-9 Antigen; C524942:MIRN155 microRNA, human; C524940:MIRN21 microRNA, human; C543800:MIRN210 microRNA, human; C543351:MIRN25 microRNA, human; D035683:MicroRNAs